Further research, including larger animal studies and carefully designed clinical trials, would be needed before GLP-1 agonists could be considered as a treatment for pulmonary fibrosis associated with COVID-19
Previous studies have demonstrated that the characteristic CT findings of COVID-19, such as ground-glass opacities and consolidation, are determined by its comprehensive pathophysiological processesincluding gas-blood barrier dysfunction, microthrombosis, cytokine storm, oxidative stress, hyaline membrane formation, and bronchospasmwhich are also associated with the development of post-COVID pulmonary fibrosis [14, 44,45,46]
While we tested low-dose aCD3, other immune interventions, including anti-thymocyte globulin (ATG), may also be candidates for combination strategies
however, in subsequent years there are savings of $4.2 million per year